- Home
- DTSQ vs ADAG Comparison
DTSQ vs ADAG Comparison
Compare DTSQ & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSQ
- ADAG
- Stock Information
- Founded
- DTSQ 2022
- ADAG 2011
- Country
- DTSQ United States
- ADAG China
- Employees
- DTSQ N/A
- ADAG N/A
- Industry
- DTSQ
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- DTSQ
- ADAG Health Care
- Exchange
- DTSQ NYSE
- ADAG Nasdaq
- Market Cap
- DTSQ 91.7M
- ADAG 91.4M
- IPO Year
- DTSQ 2024
- ADAG 2021
- Fundamental
- Price
- DTSQ N/A
- ADAG $1.88
- Analyst Decision
- DTSQ
- ADAG Strong Buy
- Analyst Count
- DTSQ 0
- ADAG 1
- Target Price
- DTSQ N/A
- ADAG $8.00
- AVG Volume (30 Days)
- DTSQ 353.0
- ADAG 92.2K
- Earning Date
- DTSQ 01-01-0001
- ADAG 07-24-2025
- Dividend Yield
- DTSQ N/A
- ADAG N/A
- EPS Growth
- DTSQ N/A
- ADAG N/A
- EPS
- DTSQ 0.28
- ADAG N/A
- Revenue
- DTSQ N/A
- ADAG $103,204.00
- Revenue This Year
- DTSQ N/A
- ADAG $6,488.89
- Revenue Next Year
- DTSQ N/A
- ADAG $57.50
- P/E Ratio
- DTSQ $37.05
- ADAG N/A
- Revenue Growth
- DTSQ N/A
- ADAG N/A
- 52 Week Low
- DTSQ $9.96
- ADAG $1.33
- 52 Week High
- DTSQ $10.47
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- DTSQ N/A
- ADAG 44.87
- Support Level
- DTSQ N/A
- ADAG $1.74
- Resistance Level
- DTSQ N/A
- ADAG $2.10
- Average True Range (ATR)
- DTSQ 0.00
- ADAG 0.10
- MACD
- DTSQ 0.00
- ADAG -0.02
- Stochastic Oscillator
- DTSQ 0.00
- ADAG 16.67
About DTSQ DT CLOUD STAR ACQUISITION CORP
DT Cloud Star Acquisition Corp is a blank check company.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.